KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exelixis (EXEL) Research & Development (2016 - 2026)

Exelixis has reported Research & Development over the past 17 years, most recently at $213.2 million for Q1 2026.

  • Quarterly results put Research & Development at $213.2 million for Q1 2026, down 14.36% from a year ago — trailing twelve months through Jan 2026 was $825.0 million (down 9.38% YoY), and the annual figure for FY2026 was $825.0 million, down 9.38%.
  • Research & Development for Q1 2026 was $213.2 million at Exelixis, up from $199.2 million in the prior quarter.
  • Over the last five years, Research & Development for EXEL hit a ceiling of $336.8 million in Q4 2022 and a floor of $156.7 million in Q2 2022.
  • Median Research & Development over the past 5 years was $217.9 million (2024), compared with a mean of $229.5 million.
  • Biggest five-year swings in Research & Development: skyrocketed 512.41% in 2022 and later tumbled 33.08% in 2024.
  • Exelixis' Research & Development stood at $336.8 million in 2022, then dropped by 27.36% to $244.7 million in 2023, then dropped by 9.03% to $222.6 million in 2024, then decreased by 10.52% to $199.2 million in 2025, then increased by 7.07% to $213.2 million in 2026.
  • The last three reported values for Research & Development were $213.2 million (Q1 2026), $199.2 million (Q4 2025), and $200.4 million (Q3 2025) per Business Quant data.